1. Home
  2. SUZ vs ABVX Comparison

SUZ vs ABVX Comparison

Compare SUZ & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Suzano S.A.

SUZ

Suzano S.A.

HOLD

Current Price

$8.36

Market Cap

10.8B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$129.54

Market Cap

9.7B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUZ
ABVX
Founded
1924
2013
Country
Brazil
France
Employees
N/A
67
Industry
Paper
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
10.8B
9.7B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
SUZ
ABVX
Price
$8.36
$129.54
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
$131.31
AVG Volume (30 Days)
2.8M
885.7K
Earning Date
05-11-2026
03-23-2026
Dividend Yield
2.15%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.28
$52.14
Revenue Next Year
$13.57
$4,132.27
P/E Ratio
$5.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.11
$5.70
52 Week High
$11.54
$148.83

Technical Indicators

Market Signals
Indicator
SUZ
ABVX
Relative Strength Index (RSI) 37.12 62.16
Support Level $8.11 $106.03
Resistance Level $9.66 $138.49
Average True Range (ATR) 0.19 5.46
MACD 0.01 0.91
Stochastic Oscillator 27.11 92.97

Price Performance

Historical Comparison
SUZ
ABVX

About SUZ Suzano S.A.

Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: